Facing omicron 'curveball,' Inovio seeks endpoint switch amid fear it will strike out against original goal

The long wait for phase 3 data on Inovio Pharmaceuticals' COVID-19 vaccine just got longer. With DNA vaccine INO-4800 generating significantly lower antibodies against omicron than the original SARS-CoV-2, Inovio has paused enrollment and asked regulators to change the primary endpoint to prevention of severe disease.